Abstract |
This 4 year study reports on a pharmacokinetic study for the widely used regimen of cis-platin plus continuous 5-day 5-FU as first-line chemotherapy of head and neck cancer, and the benefit of such data for real-time therapy management. Pharmacokinetic analysis of 177 cycles for 77 patients from a group of 89 patients (group 1; 228 cycles) revealed that both the time-concentration product (AUC) for the entire cycle and the half-cycle AUC (AUC0-3 days) were predictive of cycle toxicity. Real-time analysis of individual AUC0-3 days was used to decide whether to reduce the dose during the second half of the cycle for a total of 249 cycles (81 patients; group 2). The dose in the second half of the course was reduced in 40% of the group 2 courses. There was a statistical difference in complete response rates between group 1 (31%) and group 2 (47%), (0.02 less than P less than 0.05) and a statistically significant reduction was observed in the incidence of toxic cycles (greater than grade 2, group 1 = 20% versus group 2 = 12.4%; 0.02 less than P less than 0.05). Pharmacokinetic follow-up of these patients has proved to be an objective means to improve therapeutic index significantly.
|
Authors | J Santini, G Milano, A Thyss, N Renee, P Viens, P Ayela, M Schneider, F Demard |
Journal | British journal of cancer
(Br J Cancer)
Vol. 59
Issue 2
Pg. 287-90
(Feb 1989)
ISSN: 0007-0920 [Print] England |
PMID | 2930694
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy)
- Drug Administration Schedule
- Female
- Fluorouracil
(administration & dosage, adverse effects, pharmacokinetics)
- Head and Neck Neoplasms
(drug therapy)
- Humans
- Male
- Middle Aged
- Prospective Studies
- Retrospective Studies
|